Vialwirebiotech, curated
October 2, 2026, 7:42 AM
June 10, 2026
- 6:09 AM · Pharmaceutical Technology6:09 AMAditxt and Ignite announce merger plans with strategic partner — Pharmaceutical Technology
- 4:25 AM · Pharmaceutical Technology4:25 AMMHRA to roll out new AI sandbox for medicines development — Pharmaceutical Technology
June 9, 2026
- 12:21 PM · BioPharma Dive12:21 PMMerck, Gilead report mixed outcomes in key lung cancer, HIV studies — BioPharma Dive
- 12:00 PM · BioWorld12:00 PM‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios — BioWorld
- 12:00 PM · BioWorld12:00 PMMed-tech IPO window holds with $1.51B raised through May in 2026 — BioWorld
- 12:00 PM · BioWorld12:00 PMGLP-1s and more weigh in at ADA — BioWorld
- 12:00 PM · BioWorld12:00 PMInnovent submits NDA for CLDN18.2 ADC for gastric cancer — BioWorld
- 12:00 PM · BioWorld12:00 PMNMPA gives conditional nods to drugs by Lupeng, Vcare, Staidson — BioWorld
- 12:00 PM · BioWorld12:00 PMJapan backs Oncolys virus therapy for esophageal cancer — BioWorld
- 11:50 AM · BioPharma Dive11:50 AMStealthy startup Treeline plans a reverse merger — BioPharma Dive
- 11:39 AM · Pharmaceutical Technology11:39 AMADA26: Oral PCSK9 inhibitor enlicitide delivers robust LDL-C lowering — Pharmaceutical Technology
- 11:39 AM · Pharmaceutical Technology11:39 AMADA26: Early data for teplizumab demonstrates promise for slowing T1D progression — Pharmaceutical Technology
- 10:50 AM · STAT News
- 10:32 AM · Drug Discovery World10:32 AMCrystalys doses first patients in Phase II gout trial — Drug Discovery World
- 9:23 AM · Wired — Science9:23 AMLongevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss — Wired — Science
- 9:18 AM · PharmaVoice
- 9:00 AM · BioWorld9:00 AMEngitix seals GSK deal for targets to reverse liver fibrosis — BioWorld
- 9:00 AM · BioWorld9:00 AMGrant supports Harness Therapeutics’ Parkinson’s disease program — BioWorld
- 9:00 AM · BioWorld9:00 AMFlobiotech and UCLA Health partner in neurodegeneration — BioWorld
- 9:00 AM · BioWorld9:00 AMCity Therapeutics advances RNAi pipeline with series B financing — BioWorld
- 9:00 AM · BioWorld9:00 AMModerna’s mRNA-4194 cleared for clinic for Lynch syndrome — BioWorld
- 9:00 AM · BioWorld9:00 AMGen1e Lifesciences receives US FDA designations for GEn-1123 — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMVerdiva Bio presents preclinical data on obesity treatments — Drug Discovery World
- 5:05 AM · Pharmaceutical Technology5:05 AMPfizer’s Hympavzi secures FDA expanded indications for haemophilia — Pharmaceutical Technology
- 2:48 AM · STAT News2:48 AMSTAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B — STAT News
June 8, 2026
- 4:30 PM · Nikkei Asia4:30 PMHong Kong's urban development near China border draws AstraZeneca, others — Nikkei Asia
- 1:35 PM · BioPharma Dive1:35 PMRoche stakes $700M on Nurix’s protein-degrading drug — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMIncyte nabs potential VWD game-changer in Vega deal; J&J buys Firefly — BioWorld
- 12:00 PM · BioWorld12:00 PMClinical footwork pays off in Tango’s PDAC combo phase I/II — BioWorld
- 11:26 AM · BioPharma Dive11:26 AMJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B — BioPharma Dive
- 11:01 AM · BioPharma Dive11:01 AMADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option — BioPharma Dive
- 9:17 AM · STAT News9:17 AMSTAT+: J&J spends $1 billion to enter KRAS race for cancer treatments — STAT News
- 9:00 AM · BioWorld9:00 AMLBL-051: Broad immune targeting in autoimmune disease — BioWorld
- 9:00 AM · BioWorld9:00 AMATG-207 shows efficacy in EAE with reduced cytokine release — BioWorld
- 9:00 AM · BioWorld9:00 AMChina’s NMPA clears Hansoh’s HS-10541 for clinic — BioWorld
- 9:00 AM · BioWorld9:00 AMAntares Therapeutics divulges new CDK2/cyclin E1 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMSkape Bio unlocks GPCR targets with de novo-designed miniproteins — BioWorld
- 9:00 AM · BioWorld9:00 AMEikon Therapeutics discloses new USP1 inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMAmphista’s BRD9 degrader gains IND clearance for AML — BioWorld
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMOnkure Therapeutics patents new PI3Kα mutant inhibitors — BioWorld
- 9:00 AM · BioWorld9:00 AMDual ABCB4/ABCB11 modulation shows promise in cholestatic disease models — BioWorld